Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1986 Mar 1;163(3):588-602.
doi: 10.1084/jem.163.3.588.

Antibodies to basement membrane collagen and to laminin are present in sera from patients with poststreptococcal glomerulonephritis

Antibodies to basement membrane collagen and to laminin are present in sera from patients with poststreptococcal glomerulonephritis

N A Kefalides et al. J Exp Med. .

Abstract

Sera from patients with poststreptococcal glomerulonephritis (PSGN) known to have antibodies to proteoglycans were studied for the presence of antibodies against other basement membrane (BM) components. BM collagen (type IV) was isolated in the native state by extracting bovine anterior lens capsule (ALC) with 0.5 M acetic acid. The 7-S (collagenous) domain and the NC-1 (noncollagenous) domain of type IV collagen were obtained after bacterial collagenase digestion of ALC followed by gel filtration. Laminin was isolated from the mouse EHS tumor and fibronectin from human plasma. Immunologic studies, using an ELISA and electroimmunoblot, revealed the presence of antibodies that reacted with intact, native type IV collagen and the 7-S collagenous domain of this molecule. Reaction with the NC-1 (noncollagenous) domain was minimal, and not higher than that obtained with control sera. Laminin reaction strongly with the patients' sera, but fibronectin did not. Unlike sera from patients with Goodpasture syndrome, which contain antibodies primarily against the NC-1 (noncollagenous) domain of type IV collagen, sera from patients with acute PSGN contain antibodies against all the major macromolecular components of BM. This difference in immunologic reactivity may account for the observed differences in the pathologic picture at the glomerular level.

PubMed Disclaimer

References

    1. J Exp Med. 1966 Feb 1;123(2):399-412 - PubMed
    1. Coll Relat Res. 1985 Jun;5(3):233-44 - PubMed
    1. Biochemistry. 1968 Sep;7(9):3103-12 - PubMed
    1. Biochemistry. 1969 Nov;8(11):4613-21 - PubMed
    1. Nature. 1970 Aug 15;227(5259):680-5 - PubMed

Publication types

MeSH terms